Based on comparisons to other clinical stage biotechs with much less promising drugs you are very correct.... I use stock screen regularly and there are literally hundreds of clinical stage ( no revenue) biotechs that are trading between 2-20 per share. I look at some of them and many are not as far long cytodyn in approval process. And usually the drugs they are developing do not have no where near as lucrative indications as cytodyn.